Monoclonal Antibody ABX-EGF in Treating Patients With Renal (Kidney), Prostate, Pancreatic, Non-Small Cell Lung, Colon or Rectal, Esophageal, or Gastroesophageal Junction Cancer

You may be eligible if

• DISEASE CHARACTERISTICS:
• Histologically confirmed diagnosis of 1 of the following:
• * Renal cell cancer (RCC)
• * Prior nephrectomy required
• * Prostate cancer
• * Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
• * Failed prior hormonal therapy (e.g., antiandrogen, luteinizing hormone-releasing hormone inhibitor, or orchiectomy)
• * Pancreatic cancer
• * Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
• * Non-small cell lung cancer
• * Failed at least 1 prior standard therapy regimen for unresectable metastatic disease
• * Colorectal cancer
• * Received 1 or more prior chemotherapy regimen(s) for advanced metastatic disease
• * Esophageal cancer
• * Failed prior primary therapy (e.g., surgery, radiotherapy, or chemotherapy)
• * Gastroesophageal junction cancer
• Evaluable disease
• Epidermal growth factor receptor overexpression
• * Tumor tissue must yield the sum of 1+, 2+, or 3+ staining in at least 10% of evaluated tumor cells
• No uncontrolled brain metastases
• No evidence of disease progression or regression after a 30-day washout period
• PATIENT CHARACTERISTICS:
• Age:
• 18 and over
• Performance status:
• Karnofsky 70-100% OR
• ECOG 0-1
• Life expectancy:
• Not specified
• Hematopoietic:
• Absolute neutrophil count greater than 1,000/mm\^3
• Platelet count greater than 100,000/mm\^3
• Hepatic:
• AST/ALT no greater than 2 times upper limit of normal (ULN) (3 times ULN for liver metastases)
• Alkaline phosphatase no greater than 2 times ULN (3 times ULN for liver metastases)
• Renal:
• Creatinine less than 2.2 mg/dL
• NCI renal toxicity no greater than grade 2
• No hypercalcemia (antihypercalcemic therapy allowed)
• Cardiovascular:
• Ejection fraction at least 45% by MUGA
• No abnormal ECG or MUGA
• No myocardial infarction within the past year
• Pulmonary:
• No abnormal chest x-ray
• FEV\_1 greater than 50% of predicted
• Other:
• No known allergy to ingredients of study drug
• No known allergy to Staphylococcus aureus Protein A
• HIV negative
• No chronic medical or psychiatric condition that would preclude study compliance
• Not pregnant or nursing
• Negative pregnancy test
• Fertile patients must use effective contraception during and for 2 months after study participation
• PRIOR CONCURRENT THERAPY:
• Biologic therapy:
• At least 30 days since prior biologic therapy (e.g., antibodies, cytokines, or co-stimulatory pathway inhibitors)
• No other concurrent biologic therapy
• Chemotherapy:
• See Disease Characteristics
• At least 6 weeks since prior chemotherapy and recovered
• No prior chemotherapy for RCC
• No prior anthracyclines
• No concurrent chemotherapy
• Endocrine therapy:
• See Disease Characteristics
• Concurrent steroids allowed
• Concurrent hormonal therapy allowed
• Radiotherapy:
• See Disease Characteristics
• No prior mediastinal radiotherapy
• No concurrent radiotherapy
• Surgery:
• See Disease Characteristics
• Recovered from any recent prior surgery
• Other:
• At least 30 days since prior investigational drug or device
• At least 30 days since prior systemic therapy
• No other concurrent investigational drugs
• No other concurrent systemic agents or cancer therapy